Bausch Health Announces Executive and Board Changes

Ticker: BHC · Form: 8-K · Filed: May 15, 2025 · CIK: 885590

Sentiment: neutral

Topics: management-change, board-of-directors, executive-compensation

TL;DR

Bausch Health shakes up leadership and board.

AI Summary

On May 9, 2025, Bausch Health Companies Inc. announced changes in its executive team and board of directors. The filing details the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for key executives. Specific names and dollar amounts related to these changes were not detailed in the provided excerpt.

Why It Matters

Changes in leadership and board composition can signal shifts in company strategy, governance, or future performance.

Risk Assessment

Risk Level: medium — Executive and board changes can introduce uncertainty regarding future strategy and operational direction.

Key Players & Entities

FAQ

What specific roles have been affected by the executive and director changes?

The filing indicates the departure of certain officers and directors, and the election of new directors, but does not specify the exact roles in the provided excerpt.

When were these changes effective?

The date of the earliest event reported is May 9, 2025, and the date as of change is also May 9, 2025.

Are there any details on new compensatory arrangements for officers?

The filing mentions 'Compensatory Arrangements of Certain Officers' as an item information, but specific details are not included in the excerpt.

What is Bausch Health's primary industry?

Bausch Health Companies Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.

What was Bausch Health's former name?

Bausch Health Companies Inc. was formerly known as Valeant Pharmaceuticals International, Inc. and BIOVAIL Corp.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 15, 2025 regarding Bausch Health Companies Inc. (BHC).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing